AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Avita Medical Ltd (NASDAQ:RCEL)
5.55 USD
-0.250 4.310%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.8 |
|---|---|
| Change | -0.250 4.310% |
| 52 W H/L (in USD) | 21.700/7.510 |
| EBITDA (in USD) | -49.163M |
| PE Ratio | -- |
| Volume | 431640 |
| Diluted Eps TTM | -1.88 |
| Total Assets (in USD) | 98.264M |
|---|---|
| Total Liabilities (in USD) | 13.524M |
| Revenue TTM (in USD) | 50.697M |
| Cash (in USD) | 18.164M |
| Market Cap (in USD) | 222.651 M |
| Revenue Per Share TTM | 1.993 |
| Gross Profit TTM (in USD) | 28.38M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Avita Medical Ltd
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Employees: 207
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. James M. Corbett | CEO, Pres & Exec. Director | 1958 |
| 2. | Mr. Michael Bria Holder MBA | Chief Financial Officer | 1963 |
| 3. | Ms. Kathy M. McGee | Chief Operating Officer | 1966 |
| 4. | Mr. Andrew Quick | Chief Technology Officer | 1971 |
| 5. | Ms. Donna Shiroma | Gen. Counsel & Sec. | 1962 |
| 6. | Ms. Erin Liberto | Chief Commercial Officer | 1975 |
| 7. | Mr. David Fencil | VP of Global Operations | NA |
| 8. | Ms. Debbie Garner | VP of Global Marketing | NA |
| 9. | Mr. James M. Corbett | CEO, President & Executive Director | 1958 |
| 10. | Mr. David O'Toole | Chief Financial Officer | 1959 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+0.303 0.222% | 135.78 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+1.380 0.363% | 377.22 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.314 0.355% | 88.21 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+1.940 1.968% | 98.21 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -26.629M | - | -42.026M | -24.75M | -24.75M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -26.665M | - | -42.03M | -24.624M | -24.624M |
| Selling General Administrative | 23.33M | - | 34.621M | 12.667M | 12.667M |
| Gross Profit | 28.38M | - | 11.29M | 4.207M | 4.207M |
| Reconciled Depreciation | 0.568M | - | 0.715M | 0.465M | 0.265M |
| Ebit | -27.505M | -25.076M | -41.993M | -24.724M | -24.724M |
| Ebitda | -26.045M | - | -41.528M | -24.724M | -24.724M |
| Depreciation And Amortization | 1.46M | - | 0.465M | 0M | 0M |
| Operating Income | -27.505M | - | -42.679M | -24.724M | -24.724M |
| Other Operating Expenses | 61.926M | 1.59M | 56.942M | 30.44M | 30.44M |
| Interest Expense | 0.016M | 0M | 0.033M | 0.026M | 0.026M |
| Tax Provision | 0.036M | - | 0.038M | 0.004M | -0.126M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -0.016M | - | -0.022M | -0.033M | -0.026M |
| Income Tax Expense | 0.036M | 0.042M | 0.004M | -0.126M | -0.126M |
| Total Revenue | 34.421M | - | 14.263M | 5.396M | 5.396M |
| Total Operating Expenses | 55.885M | - | 53.969M | 29.251M | 29.251M |
| Cost Of Revenue | 6.041M | - | 2.973M | 1.189M | 1.189M |
| Total Other Income Expense Net | 0.876M | - | 0.686M | 0.32M | 0.32M |
| Net Income From Continuing Ops | -26.665M | - | -26.583M | -42.03M | -24.624M |
| Net Income Applicable To Common Shares | -26.665M | -25.142M | -26.583M | -42.03M | -25.102M |
Balance Sheet
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Total Assets | 98.264M | - | 82.462M | 25.729M | 25.729M |
| Intangible Assets | 0.465M | - | 0.364M | 0.225M | 0.225M |
| Other Current Assets | 2.476M | 0.203M | 0.99M | 1.091M | 1.091M |
| Total Liab | 13.524M | - | 10.061M | 4.866M | 4.866M |
| Total Stockholder Equity | 84.74M | - | 72.401M | 20.863M | 20.863M |
| Other Current Liab | 6.885M | 0.355M | 3.376M | 0.455M | 0.455M |
| Common Stock | 0.003M | 0.003M | 0.003M | 143.065M | 143.065M |
| Capital Stock | 0.003M | - | 0.003M | 0.003M | 143.065M |
| Retained Earnings | -262.588M | -235.923M | -194.913M | -128.689M | -128.689M |
| Good Will | - | - | - | - | 0M |
| Other Assets | 1.36M | 0.942M | 0.761M | 0M | 0M |
| Cash | 18.164M | - | 73.639M | 20.298M | 20.298M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 10.693M | 9.146M | 7.709M | 4.401M | 4.401M |
| Current Deferred Revenue | 0.194M | - | - | - | - |
| Net Debt | -17.246M | - | -71.722M | -20.26M | -20.26M |
| Short Term Debt | 0.612M | - | 0.878M | - | 0M |
| Short Long Term Debt | - | - | - | - | 0M |
| Short Long Term Debt Total | 0.918M | - | 1.917M | 0.038M | 0.038M |
| Other Stockholder Equity | 339.698M | 8.06M | 259.165M | 29.789M | 29.789M |
| Property Plant Equipment | 2.051M | 2.806M | 2.938M | 3.71M | 1.309M |
| Total Current Assets | 87.458M | 92.132M | 78.387M | 24.217M | 24.217M |
| Long Term Investments | 6.93M | - | - | - | 0M |
| Short Term Investments | 61.178M | - | - | - | 0M |
| Net Receivables | 4.96M | 3.513M | 2.432M | 2.087M | 2.087M |
| Long Term Debt | - | - | - | - | 0M |
| Inventory | 2.125M | 2.132M | 1.125M | 0.741M | 0.741M |
| Accounts Payable | 3.002M | 2.708M | 4.333M | 3.945M | 3.945M |
| Accumulated Other Comprehensive Income | 7.627M | - | 8.146M | 6.488M | 6.488M |
| Non Currrent Assets Other | 1.36M | - | 0.001M | 0M | 0M |
| Non Current Assets Total | 10.806M | - | 4.075M | 1.512M | 1.512M |
| Capital Lease Obligations | 0.918M | - | 0.878M | 1.917M | 0.038M |
| Long Term Debt Total | - | - | - | - | 0.001M |
Cash Flow
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | -19.332M | -49.55M | -1.174M | -0.847M | -1.257M |
| Total Cashflows From Investing Activities | -19.332M | -50.208M | -1.174M | -0.847M | -1.227M |
| Total Cash From Financing Activities | 0.9M | 64.065M | 77.057M | 77.057M | 28.922M |
| Net Income | -26.665M | -25.142M | -42.03M | -24.624M | -24.624M |
| Change In Cash | -37.548M | -4.254M | 53.466M | -39.623M | -19.249M |
| Begin Period Cash Flow | 55.712M | 110.947M | 20.374M | 20.374M | 10.383M |
| End Period Cash Flow | 18.164M | 55.712M | 73.84M | -19.249M | -19.249M |
| Total Cash From Operating Activities | -19.09M | -18.037M | -22.747M | -19.249M | -19.249M |
| Depreciation | 0.568M | 0.673M | 0.465M | 0.265M | 0.265M |
| Other Cashflows From Investing Activities | - | - | - | - | 0M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | -0.371M | -0.144M | -0.468M | 0.069M | 0.069M |
| Sale Purchase Of Stock | - | - | - | - | 1.223M |
| Other Cashflows From Financing Activities | 0.9M | -5.109M | -4.603M | -4.603M | -2.619M |
| Capital Expenditures | 0.525M | 0.487M | 0.847M | 0.847M | 1.257M |
| Change In Working Capital | -1.196M | - | 1.33M | 3.351M | 3.351M |
| Other Non Cash Items | 1.205M | - | 0.502M | 0.063M | 0.063M |
| Free Cash Flow | -19.615M | - | -23.594M | -20.096M | -19.249M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 800719 |
| 2. | iShares Russell 2000 ETF | 1 year ago | 603391 |
| 3. | SPDR® S&P Biotech ETF | 1 year ago | 400518 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 389203 |
| 5. | Fidelity Small Cap Index | 1 year ago | 258034 |
| 6. | iShares Russell 2000 Growth ETF | 1 year ago | 215060 |
| 7. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 156200 |
| 8. | Fidelity Extended Market Index | 1 year ago | 147137 |
| 9. | Vanguard Russell 2000 ETF | 1 year ago | 93760 |
| 10. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 92600 |
| 11. | Silvercrest U.S. Small Cap Growth | 1 year ago | 75491 |
| 12. | NT R2000 Growth Index Fund - NL | 1 year ago | 75459 |
| 13. | NT R2000 Index Fund - NL | 1 year ago | 69814 |
| 14. | BlackRock Extended Mkt Composite | 1 year ago | 59353 |
| 15. | Schwab Small Cap Index | 1 year ago | 57246 |
| 16. | NT R2000 Growth Index Fund - L | 1 year ago | 56625 |
| 17. | NT R2000 Index Fund - DC - NL - 2 | 1 year ago | 55442 |
| 18. | Northern Trust Russell 2000 Growth Index | 1 year ago | 54315 |
| 19. | iShares Micro-Cap ETF | 1 year ago | 53339 |
| 20. | BlackRock Extended Equity Market K | 1 year ago | 50981 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 1806149 |
| 2. | Vanguard Group Inc | 1 year ago | 1408136 |
| 3. | Geode Capital Management, LLC | 1 year ago | 528657 |
| 4. | State Street Corporation | 1 year ago | 500308 |
| 5. | Awm Investment Company Inc | 1 year ago | 496952 |
| 6. | PURA VIDA INVESTMENTS, LLC | 1 year ago | 361096 |
| 7. | Northern Trust Corp | 1 year ago | 225180 |
| 8. | Driehaus Capital Management LLC | 1 year ago | 209257 |
| 9. | Bank of New York Mellon Corp | 1 year ago | 116678 |
| 10. | Ameriprise Financial Inc | 1 year ago | 98682 |
| 11. | AQR Capital Management LLC | 1 year ago | 90600 |
| 12. | GlobeFlex Capital, L.P. | 1 year ago | 76856 |
| 13. | Soleus Capital Management, L.P. | 1 year ago | 75000 |
| 14. | 1492 Capital Management, LLC | 1 year ago | 71929 |
| 15. | Nuveen Asset Management, LLC | 1 year ago | 71738 |
| 16. | Charles Schwab Investment Management Inc | 1 year ago | 67300 |
| 17. | Morgan Stanley - Brokerage Accounts | 1 year ago | 62298 |
| 18. | Goldman Sachs Group Inc | 1 year ago | 55536 |
| 19. | Rafferty Asset Management, LLC | 1 year ago | 51600 |
| 20. | D. E. Shaw & Co LP | 1 year ago | 48129 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...